ÌìÃÀÓ°Ôº

Metabolic dysfunction-associated steatohepatitis (MASH)It is estimated that by 2030, MASH will be the #1 most frequent reason for liver transplants in the US

Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.

    ELF Infographic

    The ELF Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patients with advanced fibrosis due to MASH1

    • The only blood test with a prognostic claim in advanced fibrosis due to MASH
    • Simplifies and accelerate the risk stratification of patients with advanced fibrosis due to NASH (MASH).
    • Facilitates more timely prognostic assessments
    • Available to all patients

    The ELF Test enables accessible, effortless prognostic risk assessment in patients with advanced fibrosis due to NASH, improving patient care by stratifying those most at risk of progressing to cirrhosis and liver related events1

    1
    Subscription Button Icon
    Be the first to know about our events, training, and news